Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 121

1.
3.

Treatment of anaemia with erythropoiesis-stimulating agents in patients with chronic kidney disease does not lower mortality and may increase cardiovascular risk: a meta-analysis.

Vinhas J, Barreto C, Assunção J, Parreira L, Vaz A.

Nephron Clin Pract. 2012;121(3-4):c95-101. doi: 10.1159/000345158. Epub 2012 Nov 22. Review.

PMID:
23182871
4.

Haemoglobin targets: we were wrong, time to move on.

Strippoli GF, Tognoni G, Navaneethan SD, Nicolucci A, Craig JC.

Lancet. 2007 Feb 3;369(9559):346-50. No abstract available.

PMID:
17276756
5.

Recombinant human erythropoietin for chronic renal failure anaemia in pre-dialysis patients.

Cody J, Daly C, Campbell M, Donaldson C, Grant A, Khan I, Pennington S, Vale L, Wallace S, MacLeod A.

Cochrane Database Syst Rev. 2001;(4):CD003266. Review. Update in: Cochrane Database Syst Rev. 2005;(3):CD003266.

PMID:
11687180
6.

Haemoglobin and haematocrit targets for the anaemia of chronic renal disease.

Strippoli GF, Manno C, Schena FP, Craig JC.

Cochrane Database Syst Rev. 2003;(1):CD003967. Review. Update in: Cochrane Database Syst Rev. 2006;(4):CD003967.

PMID:
12535495
7.

Haemoglobin concentrations in chronic kidney disease.

Steinbrook R.

Lancet. 2006 Dec 23;368(9554):2191-3. No abstract available.

PMID:
17189015
8.

Target haemoglobin to aim for with erythropoiesis-stimulating agents: a position statement by ERBP following publication of the Trial to reduce cardiovascular events with Aranesp therapy (TREAT) study.

Locatelli F, Aljama P, Canaud B, Covic A, De Francisco A, Macdougall IC, Wiecek A, Vanholder R; Anaemia Working Group of European Renal Best Practice (ERBP)..

Nephrol Dial Transplant. 2010 Sep;25(9):2846-50. doi: 10.1093/ndt/gfq336. Epub 2010 Jun 29. Review.

PMID:
20591813
9.

Intravenous methoxy polyethylene glycol-epoetin beta for haemoglobin control in patients with chronic kidney disease who are on dialysis: a randomised non-inferiority trial (MAXIMA).

Levin NW, Fishbane S, Cañedo FV, Zeig S, Nassar GM, Moran JE, Villa G, Beyer U, Oguey D; MAXIMA study investigators..

Lancet. 2007 Oct 20;370(9596):1415-21. Erratum in: Lancet. 2008 Feb 2;371(9610):386.

PMID:
17950856
10.

Haemoglobin concentrations in chronic kidney disease.

Fernandes M, Sawa H, Bellini G.

Lancet. 2007 Feb 3;369(9559):365. No abstract available.

PMID:
17276763
11.

Human recombinant erythropoietin in anaemic patients on maintenance haemodialysis. Secondary effects of the increase of haemoglobin.

Zehnder C, Glück Z, Descoeudres C, Uehlinger DE, Blumberg A.

Nephrol Dial Transplant. 1988;3(5):657-60.

PMID:
3146724
12.

A systematic review and economic evaluation of epoetin alpha, epoetin beta and darbepoetin alpha in anaemia associated with cancer, especially that attributable to cancer treatment.

Wilson J, Yao GL, Raftery J, Bohlius J, Brunskill S, Sandercock J, Bayliss S, Moss P, Stanworth S, Hyde C.

Health Technol Assess. 2007 Apr;11(13):1-202, iii-iv. Review.

13.

Haemoglobin and haematocrit targets for the anaemia of chronic kidney disease.

Strippoli GF, Navaneethan SD, Craig JC.

Cochrane Database Syst Rev. 2006 Oct 18;(4):CD003967. Review.

PMID:
17054191
14.

Frequency of administration of recombinant human erythropoietin for anaemia of end-stage renal disease in dialysis patients.

Cody J, Daly C, Campbell M, Donaldson C, Grant A, Khan I, Vale L, Wallace S, MacLeod A.

Cochrane Database Syst Rev. 2002;(4):CD003895. Review. Update in: Cochrane Database Syst Rev. 2005;(3):CD003895.

PMID:
12519614
15.

Treatment of anaemia in dialysis patients with unit dosing of darbepoetin alfa at a reduced dose frequency relative to recombinant human erythropoietin (rHuEpo).

Locatelli F, Canaud B, Giacardy F, Martin-Malo A, Baker N, Wilson J.

Nephrol Dial Transplant. 2003 Feb;18(2):362-9.

PMID:
12543893
16.

A study of recombinant human erythropoietin in the treatment of anaemia of chronic renal failure in children on haemodialysis.

Van Damme-Lombaerts R, Broyer M, Businger J, Baldauf C, Stocker H.

Pediatr Nephrol. 1994 Jun;8(3):338-42.

PMID:
7917862
18.

Efficacy and tolerance of treatment with recombinant-human erythropoietin in chronic renal failure (pre-dialysis) patients.

Frenken LA, Verberckmoes R, Michielsen P, Koene RA.

Nephrol Dial Transplant. 1989;4(9):782-6.

PMID:
2516609
19.

Darbepoetin alfa effectively maintains haemoglobin concentrations at extended dose intervals relative to intravenous or subcutaneous recombinant human erythropoietin in dialysis patients.

Brunkhorst R, Bommer J, Braun J, Haag-Weber M, Gill C, Wagner J, Wagener T; German Aranesp Study Group..

Nephrol Dial Transplant. 2004 May;19(5):1224-30. Epub 2004 Feb 19.

PMID:
14993489
20.

Positive outcomes of high hemoglobin target in patients with chronic kidney disease not on dialysis: a randomized controlled study.

Akizawa T, Gejyo F, Nishi S, Iino Y, Watanabe Y, Suzuki M, Saito A, Akiba T, Hirakata H, Fukuhara S, Morita S, Hiroe M, Hada Y, Suzuki M, Akaishi M, Iwasaki M, Tsubakihara Y; KRN321 STUDY Group..

Ther Apher Dial. 2011 Oct;15(5):431-40. doi: 10.1111/j.1744-9987.2011.00931.x. Epub 2011 May 25.

PMID:
21974695

Supplemental Content

Support Center